 INGA VENTURES PRIVATE LTD. 1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli, Andheri (East), Mumbai 400 069, Maharashtra, India CIN : U67100MH2018PTC318359 Tel. No.: +91 22 26816003; Email: foods&inns.oo@ingaventures.com; Contact Person: Kavita Shah; SEBI Registration Number: INM000012698	 Pioneer Investcorp Limited 1218, 12th Floor, Maker Chambers V, Nariman Point, Mumbai 400 021 CIN: L65990MH1984PLC031909 Tel: +91 22 66186633, E-mail: projectfood@pinc.co.in Contact Person: Varun Jain SEBI registration no.: INM000002988
--	--

August 16, 2024

To,

BSE Limited
Pheeroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai – 400 001

Dear Sir/Madam,

Sub: Submission of Post Offer Advertisement

Ref: Open Offer by Raymond Simkins (“Acquirer 1”) and Milan Bhupendra Dalal (“Acquirer 2”) (hereinafter Acquirer 1 and Acquirer 2 are collectively referred to as “Acquirers”), along with Borgos Multitrade LLP deemed to be Person Acting In Concert with Acquirer 2 (“PAC”) for the purpose of this Open Offer, to the public shareholders of Foods and Inns Limited (“Target Company”) for acquisition of upto 1,90,79,617 equity shares of face value of ₹ 1/- each at a price of ₹ 147/- per fully paid up equity share pursuant to regulations 3(1), 4 and other applicable provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended (“SEBI (SAST) Regulations”).

This has reference to the captioned offer Open Offer and in terms of Regulation 18(12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto (“SEBI (SAST) Regulations”), the Post Offer Advertisement dated August 14, 2024 has been published on August 15, 2024 in the following newspapers:

Sr. No.	Newspaper	Language	Edition(s)
1	Financial Express	English	All Editions
2	Jansatta	Hindi	All Editions
3	Pratahkal	Marathi	Marathi Editions

We are enclosing herewith a copy of the newspaper clipping of the Post Offer Advertisement published in Financial Express (English).

Kindly take the above information on your record and disseminate the Post Offer Advertisement on the website of the Stock Exchange.



INGA VENTURES PRIVATE LTD.
1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli,
Andheri (East), Mumbai 400 069, Maharashtra, India
CIN : U67100MH2018PTC318359
Tel. No.: +91 22 26816003; Fax No.: +91 22 26816020;
Email: foods&inns.oo@ingaventures.com;
Contact Person: Kavita Shah;
SEBI Registration Number: INM000012698

PINC

Pioneer Investcorp Limited
1218, 12th Floor, Maker Chambers V,
Nariman Point, Mumbai 400 021
CIN: L65990MH1984PLC031909
Tel: +91 22 66186633,
E-mail: projectfood@pinc.co.in
Contact Person: Varun Jain
SEBI registration no.: INM000002988

This signature page forms an integral part of the letter to BSE Limited in relation to the proposed Open Offer of Foods and Inns Limited

For Inga Ventures Private Limited

K. Shah



Authorized Signatory

Name: Kavita Shah

Designation: Partner

Contact number: 9867501267

Email: kavita@ingaventures.com

Encl.: As Above




INGA VENTURES PRIVATE LTD.
1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli,
Andheri (East), Mumbai 400 069, Maharashtra, India
CIN : U67100MH2018PTC318359
Tel. No.: +91 22 26816003; Fax No.: +91 22 26816020;
Email: foods&inns.oo@ingaventures.com;
Contact Person: Kavita Shah;
SEBI Registration Number: INM000012698

Pioneer Investcorp Limited
1218, 12th Floor, Maker Chambers V,
Nariman Point, Mumbai 400 021
CIN: L65990MH1984PLC031909
Tel: +91 22 66186633,
E-mail: projectfood@pinc.co.in
Contact Person: Varun Jain
SEBI registration no.: INM000002988

This signature page forms an integral part of the letter to BSE Limited in relation to the proposed Open Offer of Foods and Inns Limited

For Pioneer Investcorp Limited



Authorized Signatory

Name: Varun Jain

Designation: AVP

Contact number: 8080068054

Email: varun.jain@pinc.co.in

Encl.: As Above

Extracts of the Statement of Un-audited Financial Results for the Quarter Ended 30 June 2024

Particulars	Standalone		Consolidated	
	Quarter Ended on 30/06/2024	Un-audited	Quarter Ended on 30/06/2024	Un-audited
Total income from operations (net)	660,857	851,055	660,857	851,055
Net Profit/(Loss) for a period (before tax, Exceptional and/or Extraordinary Items)	19,329	65,374	19,329	65,374
Net Profit/(Loss) for a period before tax (after Exceptional and/or Extraordinary Items)	19,329	65,374	19,329	65,374
Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	13,299	65,374	13,299	65,374
Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	13,299	65,374	13,299	65,374
Equity Share Capital	371,429	100	371,429	100
Earnings Per Share (of Rs. 1 each) (for continuing and discontinued operations) -				
1. Basic:	0.047	0.654	0.047	0.654
2. Diluted:	0.047	0.654	0.047	0.654

Note:
 The above result is an extract of the detailed format of Un-audited Standalone and Consolidated Financial Results for the quarter ended 30 June 2024 filed with Stock Exchange under Regulation 33 of the SEBI (Listing and Obligations and Disclosures Requirements) Regulations, 2015. The full format of the classified results is available on website of Stock Exchange.

Figures of the previous year have been re-grouped/re-arranged/re-classified wherever considered necessary.
 For KCD Industries India Limited
 Rajiv Darji
 Managing Director
 DIN: 02089219
 Place: Mumbai
 Date: 12th August 2024



glenmark
 GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B2, Mahalaxmi Chambers, 22, Bhubalshi Desai Road, Mumbai - 400 026;
 Corporate Office: Glenmark House B, D, Swami Marg, Chakala, Off. Western Express Highway, Andheri (E), Mumbai - 400099
 Phone No: +91 22 4018 9599 Fax No: +91 22 4018 9696 Website: www.glenmarkpharma.com Email: compliance@glennmarkpharma.com CIN: L24299MH1977PLC019882

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2024

(All amounts in million of Indian Rupees, unless otherwise stated)

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter ended 30/06/2024 (Unaudited)	Quarter ended 31/03/2024 (Refer note 7) (Unaudited)	Quarter ended 30/06/2023 (Unaudited)	Year ended 31/03/2024 (Audited)	Quarter ended 30/06/2024 (Unaudited)	Quarter ended 31/03/2024 (Refer note 7) (Unaudited)	Quarter ended 30/06/2023 (Unaudited)	Year ended 31/03/2024 (Audited)
I	Revenue from operations	22,968.75	20,771.32	20,980.62	76,497.61	32,233.02	30,160.07	29,984.72	1,16,354.56
(a)	Net sales	326.62	710.91	463.22	2,413.58	208.64	469.45	375.94	1,776.41
(b)	Other operating income	23,295.37	21,452.23	21,443.84	78,911.19	32,441.86	30,629.52	30,360.66	1,18,130.97
II	Total revenue from operations	23,295.37	21,452.23	21,443.84	78,911.19	32,441.86	30,629.52	30,360.66	1,18,130.97
III	Other income	556.46	7,862.70	493.61	11,800.24	314.92	7,731.65	197.22	6,399.94
IV	Expenses	23,851.85	29,344.93	21,937.45	90,591.43	32,756.78	38,361.17	30,557.88	1,26,530.91
(a)	Cost of materials consumed and stock-in-trade	6,481.09	6,854.51	7,967.56	29,904.11	6,657.74	7,543.09	8,302.54	31,578.22
(b)	Employee benefits expense	889.85	816.58	810.26	3,227.82	2,108.26	2,108.26	1,484.25	14,511.70
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	569.24	(21.20)	(230.84)	(1,030.70)	642.82	304.15	(608.82)	(1,956.22)
(d)	Employee benefits expense	3,844.03	3,377.45	3,344.66	14,347.75	7,104.40	7,009.55	6,812.73	28,881.43
(e)	Finance costs	153.49	833.85	619.34	2,771.10	395.82	1,485.59	1,116.08	5,189.06
(f)	Depreciation, amortisation and impairment expense	530.62	520.41	487.52	2,021.62	1,177.89	1,513.37	1,420.40	5,819.06
(g)	Other expenses	5,200.14	5,480.41	4,690.79	20,045.58	8,384.51	8,621.26	7,296.44	33,362.53
(h)	Total expenses (IV)	17,669.71	17,862.64	17,700.74	71,287.28	28,133.04	28,585.05	28,523.62	1,17,156.41
V	Profit/(Loss) before exceptional items and tax (III - IV)	6,163.14	11,479.32	4,236.71	19,304.15	4,623.34	9,776.12	2,034.26	9,374.50
VI	Exceptional items (gain)/ loss (Refer note 5)	-	(51,469.13)	316.29	(50,703.31)	-	4,467.85	5,203.23	9,009.55
VII	Profit/(Loss) before tax from continuing operations	6,163.14	62,948.45	3,920.42	70,007.46	4,623.34	5,308.28	1,514.03	384.95
VIII	Tax expense -								
(a)	Current tax	1,079.84	10,553.79	385.65	10,489.92	1,468.82	10,581.74	567.23	11,155.52
(b)	Deferred tax	565.99	6,257.71	818.21	7,834.63	(247.86)	7,112.99	570.02	7,517.93
IX	Profit/(Loss) after tax for the period from continuing operations	4,537.31	46,136.95	2,716.56	51,672.91	3,402.67	12,396.45	316.78	(18,308.50)
X	Profit/(Loss) for the period from continuing operations attributable to:								
(a)	Non-controlling interests	-	-	-	-	(0.29)	40.10	231.94	681.46
(b)	Owners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	3,402.67	(12,426.55)	144.84	(1,689.96)
XI	Profit/(Loss) before tax from discontinued operations	-	-	-	-	-	310.80	1,820.04	5,326.92
XII	Tax expense of discontinued operations:								
(a)	Current tax	-	-	-	-	-	72.73	145.99	1,294.32
(b)	Deferred tax	-	-	-	-	-	(5.69)	29.55	69.32
XIII	Profit/(Loss) after tax for the period from discontinued operations	-	-	-	-	-	243.76	1,354.50	6,378.28
XIV	Profit/(Loss) for the period from discontinued operations attributable to:								
(a)	Non-controlling interests	-	-	-	-	-	-	-	3,973.28
(b)	Owners of the Company	-	-	-	-	-	243.76	1,354.50	2,404.99
XV	Profit/(Loss) after tax for the period from continuing and discontinued operations (IX + XIII)	4,537.31	46,136.95	2,716.56	51,672.91	3,402.38	(12,142.69)	1,731.28	(14,335.22)
XVI	Profit/(Loss) for the period from continuing and discontinued operations attributable to:								
(a)	Non-controlling interests	-	-	-	-	(0.29)	40.10	231.94	681.46
(b)	Owners of the Company	4,537.31	46,136.95	2,716.56	51,672.91	3,402.67	(12,182.79)	1,499.34	(15,016.68)
XVII	Other comprehensive income from continuing operations								
(a)	Items that will not be reclassified to profit or loss	(12.52)	(9.74)	(7.50)	(73.14)	(7.01)	(94.10)	(5.52)	(163.06)
(b)	Income tax relating to items that will not be reclassified to profit or loss	4.37	9.44	2.23	25.56	2.79	26.65	2.23	42.75
(c)	Items that will be reclassified to profit or loss	-	-	-	-	60.50	846.57	(564.37)	(399.03)
(d)	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	(1.36)	(20.13)	6.80	(79.97)
XVIII	Total comprehensive income from continuing operations for the period/year	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,627.47)	(184.08)	(18,907.81)
XIX	Other comprehensive income from discontinued operations for the period/year	-	-	-	-	-	(0.19)	(0.73)	(56.23)
XX	Total comprehensive income from discontinued operations for the period/year (XIII + XIX)	-	-	-	-	-	243.57	1,353.77	3,917.05
XXI	Other comprehensive income for the period/year from continuing and discontinued operations (XVII + XIX + XX)	(8.15)	(0.30)	(5.27)	(47.58)	54.92	758.79	(561.59)	(655.53)
XXII	Total comprehensive income for the period/year from continuing and discontinued operations (XVIII + XXI)	4,529.16	46,136.65	2,711.29	51,625.33	3,457.30	(11,383.89)	1,169.69	(14,990.76)
XXIII	Total comprehensive income attributable to:								
(a)	Non-controlling interests	-	-	-	-	(0.26)	40.22	231.98	672.00
(b)	Owners of the Company	4,529.16	46,136.65	2,711.29	51,625.33	3,457.56	(11,424.11)	937.71	(15,662.76)
XXIV	Earnings per share for continuing operations (EPS) (not annualized except for the year ended 31 March)	282.19	282.19	282.17	282.19	282.19	282.19	282.17	282.19
(a)	Basic (In Rupees)	282.19	282.19	282.17	282.19	282.19	282.19	282.17	282.19
(b)	Diluted (In Rupees)	282.19	282.19	282.17	282.19	282.19	282.19	282.17	282.19
XXV	Earnings per share for continuing operations (EPS) (not annualized except for the year ended 31 March)	282.19	282.19	282.17	282.19	282.19	282.19	282.17	282.19
(a)	Basic (In Rupees)	282.19	282.19	282.17	282.19	282.19	282.19	282.17	282.19
(b)	Diluted (In Rupees)	282.19	282.19	282.17	282.19	282.19	282.19	282.17	282.19

Notes:
 1. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
 2. The above results were reviewed by the Audit Committee at its meeting held on 13th August, 2024 and approved by the Board of Directors at their meetings held on 14th August, 2024. The results for the quarter ended 30 June 2024 presented were subjected to a Limited Review by statutory auditors of the Company who have issued their report on the said results.
 3. The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
 4. As at 30th June, 2024, pursuant to Employee Stock Options Scheme 2016, 37,779 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
 5. Exceptional Items:
 Standalone:
 31.03.2024
 Exceptional item in the standalone result for the quarter and year ended 31 March 2024 is Rs. 51,469.13 million (gain) and Rs 50,703.31 million (gain) respectively, primarily comprises of stake sale (net of expenses) in Glenmark Life Science Ltd, remediation, legal, inventory provision and others.
 Pursuant to Board approval dated 21 September 2023, the Company entered into share purchase agreement with Nirma Limited (the "Buyer") for the sale of 91,865,379 equity shares representing 75.00% of the current issued and paid-up equity share capital of Glenmark Life Sciences Limited ("GLS"), a subsidiary of the Company, to the Buyer at a price of INR 615/- per share, aggregating to INR 56,511 million (subject to adjustments as agreed among the parties) in accordance with the terms of the share purchase agreement dated 21 September 2023 among the Company, GLS and the Buyer. Accordingly, 91,865,379 equity shares representing 75% of the current issued and paid-up equity share capital of the GLS, were transferred by the Company to Buyer as follows:
 A. On 6 March, 2024, 8,73,89,944 equity shares, representing 55% of the issued and paid-up equity share capital of the GLS were transferred by the Company to Buyer.
 B. On 12 March, 2024, 2,45,05,405 equity shares, representing 20% of the issued and paid-up equity share capital of the GLS were transferred by the Company to Buyer.
 As required by Ind-AS 105 'Asset Held for Sale and Discontinued Operations', GLS had been classified as discontinued operations after eliminating intercompany transactions and relevant disclosures made in the financial results.
 30.06.2023
 Exceptional item of Rs. 316.29 in the standalone result for the quarter comprises of remediation cost of manufacturing sites in India.
 Consolidated:
 31.03.2024
 Exceptional item in the Consolidated result for the quarter and full year ended 31 March 2024 is Rs. 4,467.85 million (loss) and Rs 9,009.55 million (loss) respectively primarily comprises of stake sale (net of expenses) in Glenmark Life Science Ltd, impairment of certain block at Monroe facility, De-prioritisation of certain intangibles, settlement legal cost, remediation cost and working capital adjustments.
 The US subsidiary Glenmark Pharmaceuticals Inc. USA ("Company") has entered into an agreement with the U.S. Department of Justice, Antitrust Division (DOJ) on 22 August, 2023 to resolve all of its court proceedings with the DOJ involving historical pricing practices relating to the generic drug pravastatin between 2013 and 2015. The Company has entered into a three-year Deferred Prosecution Agreement, and if the Company adheres to the terms of the agreement, including the payment of \$30 million, payable in six instalments, the DOJ will dismiss the pending Supervised Indictment.
 The US subsidiary Glenmark Pharmaceuticals Inc. USA ("Company") is likely to enter into an agreement with the U.S. Department of Justice, Antitrust Civil Division (DOJ), subject to all necessary approvals being in place, to the extent of \$30 million (including related cost), to resolve all of its Civil court proceedings with the DOJ. Due to the non-recurrence nature of the provision, the Company has classified this provision as an exceptional item in the financial statements for the quarter and year ended 31 March 2024. Pursuant to all necessary approvals and on finalisation of settlement agreements, the crystallised liability will be accounted after adjusting the provisions in this respect.
 Exceptional item in the Consolidated result for the quarter and full year ended 31 March 2024 includes Rs. 3,108.41 million (loss) and Rs 6,884.30 million (loss) respectively comprises of the U.S. Department of Justice, Antitrust Division (DOJ) settlement related cost and remediation cost of manufacturing sites in USA.
 The Board of Directors of Glenmark Pharmaceuticals Inc. USA in their meeting held on 23 May 2024 decided to impair the block of OSD & Nebulizer within the manufacturing facility located in Monroe.
 The decision was taken considering the high level of production amidst pricing pressure & competition in the US market.
 The focus, going forward, will be only on injectables where complex generic products would be commercialized, mainly for US market.
 In accordance with the provisions of Ind AS 10 Events Occurring After Reporting Period, a total charge of Rs. 21,789.85 Mn (Rs 263.2 million) has been accrued as at 31 March, 2024 (including working capital adjustments).
 Exceptional item also includes de-prioritisation of certain intangibles of Glenmark Specialty SA aggregating to Rs 11,000.77 Mn (Rs 133 million) and the consequent effect under the Accounting Standard Ind AS 36 Impairment of Intangible Assets.
 30.06.2023
 Exceptional item of Rs. 520.23 in the consolidated result for the quarter comprises of remediation cost of manufacturing sites in India and Monroe (USA).
 On 11 and 12, 2024, the Company sold its entire holding of 96,09,571 Equity Shares representing 7.84% of the total issued and paid-up equity share capital of the Glenmark Life Sciences Limited through the offer dated July 10, 2024 for sale through the stock exchange mechanism.
 The figures for the quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended 31st December 2023.
 8. The list of subsidiaries as of 30 June, 2024 is provided in Annexure A.
 9. Diluted EPS has been computed considering the effect of conversion of ESOPs.
 10. Previous period's figures have been re-grouped/classified to render them comparable with the figures of the current period.

Annexure A
 Glenmark Pharmaceuticals Limited
 List of entities included in the consolidated financial results for the quarter ended 30 June 2024
 1. Glenmark Pharmaceuticals Europe Ltd., U.K. 2. Glenmark Pharmaceuticals S.R.O. 3. Glenmark Pharmaceuticals SK, S.R.O. 4. Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S.A.) 5. Glenmark Holding S.A. 6. Glenmark Pharmaceuticals SP z.o.o. 7. Glenmark Pharmaceuticals Inc. & Glenmark Therapeutics Inc. 8. Glenmark Farmaceutica Ltda 10. Glenmark Generics S.A 11. Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 12. Glenmark Pharmaceuticals Peru SAC 13. Glenmark Pharmaceuticals Colombia SAS, Colombia 14. Glenmark Uruguay S.A. 15. Glenmark Pharmaceuticals Venezuela, C.A 16. Glenmark Dominicana S.R.L 17. Glenmark Pharmaceuticals Egypt S.A.E. 18. Glenmark Pharmaceuticals FZE 19. Glenmark Impex L.L.C 20. Glenmark Pharmaceuticals Inc. 21. Glenmark Pharmaceuticals (Nigeria) Ltd. 22. Glenmark Pharmaceuticals Malaysia Sdn Bhd 23. Glenmark Pharmaceuticals (Australia) Pty Ltd 24. Glenmark South Africa (pty) Ltd 25. Glenmark Pharmaceuticals South Africa (pty) Ltd 26. Glenmark Pharmaceuticals (Thailand) Co. Ltd 27. Glenmark Pharmaceuticals B.V. 28. Glenmark Arzneimittel GmbH 29. Glenmark Pharmaceuticals Canada Inc. 30. Glenmark Pharmaceuticals Kenya Ltd 31. Vivo Farmaceutica S.L. Spain 32. Glenmark Pharmaceuticals 33. Glenmark Pharmaceuticals (Brazil) S.A. 34. Glenmark Pharmaceuticals (India) Pvt. Ltd. 35. Glenmark Pharmaceuticals (Ukraine) LLC 36. Glenmark Pharmaceuticals Ecuador S.A. 37. Glenmark Pharmaceuticals Singapore Pte. Ltd. 38. Ichnos Sciences Biopharmaceuticals SA 39. Ichnos Sciences Inc. USA 40. Glenmark Life Science Limited (upto 6th March 2024) 41. Glenmark Healthcare Limited (with effect from 12th May 2023) 42. Glenmark Pharmaceuticals SPA (with effect from 1st March 2023) 43. Ichnos Pharma S.R.L. (with effect from 10th February 2024) 44. Glenmark Arzneimittel GmbH - Austria (with effect from 9th November 2023)

For and on behalf of the Board of Directors
 Glenn Saldanha
 Chairman & Managing Director
 Mumbai, 14 August 2024

POST OFFER ADVERTISEMENT UNDER REGULATION 18 (12) OF SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011, AND AMENDMENTS THERETO FOR THE ATTENTION OF THE PUBLIC SHAREHOLDERS OF

FOODS AND INNS LIMITED

CIN: L55200MH1967PLC013837
 Registered Office: Uday Bhawan, 2nd Floor-29, Waghbandi Hirchand Marg, Ballard Estate, Mumbai City, Mumbai, Maharashtra, India-400038.
 Corporate Office: J. N. Heredia Marg, Hamilton House, 3rd floor, Ballard Estate, Mumbai, Maharashtra, India, 400038
 Contact No: +91 22 261 3102
 Email ID: cs@foodsandinns.com. Website: https://www.foodsandinns.com/

Open Offer for acquisition of up to 1,90,79,617 fully paid-up equity shares of face value of ₹1 each representing 26.00% of the Expanded Voting Share Capital of Foods and Inns Limited ("Target Company") at a price of ₹147 per equity share from the public shareholders of the Target Company by Raymond Simkins ("Acquirer 1") and Milan Bhupendra Datal ("Acquirer 2") (hereinafter "Acquirer 1" and "Acquirer 2" are collectively referred to as "Acquirers"), along with Borgos Multitrade LLP (deemed to be Person Acting in Concert with Acquirer 2 or "PAC"), for the purpose of the Open Offer pursuant to and in compliance with Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and amendments thereto ("SEBI (SAST) Regulations, 2011") ("Open Offer" or "Offer").
 This post-offer advertisement ("Post-Offer Advertisement") is issued by Inga Ventures Private Limited and Pioneer Investorcorp Limited ("Managers to the Open Offer"), in respect of the Open Offer, for and on behalf of the Acquirers along with the PAC to the Public Shareholders of the Target Company, pursuant to and in compliance with Regulation 18 (12) of SEBI (SAST) Regulations, 2011. The detailed public statement dated April 16, 2024 ("Detailed Public Statement" or "DPS") with respect to the aforementioned Offer was published on April 18, 2024 in the following newspapers:

Newspaper	Language	Edition(s)
Financial Express	English	All Editions
Jansatta	Hindi	All Editions
Pratahkal	Marathi	Marathi Edition

The Shareholders of the Target Company are requested to kindly note the following information with respect to the Open Offer:

1) Name of the Target Company	: Foods and Inns Limited
2) Name of the Acquirer(s) and PAC	: 1) Raymond Simkins : Acquirer 1 2) Milan Bhupendra Datal : Acquirer 2 3) Borgos Multitrade LLP : PAC
3) Name of the Manager to the Offer	: 1) Inga Ventures Private Limited 2) Pioneer Investorcorp Limited
4) Name of the Registrar to the Offer	: Link Intime India Private Limited
5) Offer Details:	